Diagnostic Specialty Antibodies Market by Type (Primary, Secondary), Clonality (Monoclonal, Polyclonal), Technique (WB, Rapid Test, IHC, IP), Conjugate, and Application (Dengue, Malaria, Hepatitis, HIV, E. coli , Tuberculosis, Pneumonia, Cancer)- Forecast to 2029

The Diagnostic Specialty Antibodies Market is expected to grow at a CAGR of 4.6% from 2022–2029 to reach $39.99 billion by 2029. Antibodies are used for therapeutic and diagnostic purposes. In diagnosis procedures, the sample containing antigens binds to the antibodies and assists in the diagnosis procedure. Diagnostic antibodies are used in the diagnosis of both infectious and chronic diseases. It is widely used in diagnosing cancer and infectious diseases. Additionally, it is used in pregnancy detection and for monitoring drug action in the body.

The increasing incidences of infectious diseases, cancer, autoimmune diseases, and pregnancy, the availability of funding for diagnosis of various diseases by different organizations, increasing number of fundings for clinical trials involving the use of diagnostic antibodies, and product approvals of test kits containing diagnostic antibodies are factors driving the growth of this market.

In addition, the high prevalence of diseases in emerging countries and the initiatives by the public and private organizations for improving the diagnosis activities for eradicating infectious diseases are expected to offer significant opportunities for the growth of this market.

                                                         Click here to: Get Free Request Sample Copy of this report

COVID-19 Impact Assessment

The outbreak of the COVID-19 pandemic impacted the diagnostic specialty antibodies market both positively and negatively. The surge in COVID-19 cases increased the demand for point-of-care test kits containing antibodies due to their capability to provide faster results than other testing methods. To perform mass testing, public organizations in various countries purchased a considerable number of test kits. For instance, the WHO in September 2020, partnered with Africa Centers for Disease Control and Prevention (Africa CDC), Access to covid-19 Tools (ACT) Accelerator, the Clinton Health Access Initiative (CHAI), the Bill & Melinda Gates Foundation, the Foundation for Innovative New Diagnostics (FIND), the Global Fund, and UNITAID for providing COVID-19 antigen test kits to the low and middle-income countries.

Similarly, the European Commission in December 2020 signed an agreement with F. Hoffmann-La Roche AG (Switzerland) and Abbott Laboratories (U.S.) for purchasing 20 million rapid antigen tests for mass testing the EU Member States. The expected third wave of COVID-19 is further expected to increase the demand for antibody-based testing in the future.

The number of unintended pregnancies increased significantly worldwide due to the disruptions caused by the COVID-19 pandemic. The UN Population Fund on 11th March 2021 reported that around 12 million women did not have access to contraceptives during the pandemic due to mobility restrictions, supply chain disruptions, and the reluctance of people to visit hospitals and clinics in fear of developing an infection. The UN Population Fund stated that this problem is expected to cause 1.4 million unintended pregnancies in 2021 globally.

Regulatory authorities worldwide are actively providing approval to antibody-based test kits to support the mass screening across countries. These initiatives are further expected to have a positive impact on the market.

However, the temporary supply chain disruption due to nationwide lockdowns led to the shortage of test kits across numerous countries; thus, such disruptions hindered the growth of this market to a notable extent.

Public and Private Organization Initiatives to Eradicate Infectious Diseases is Projected to Drive the Adoption of Diagnostic Antibody

Various organizations are actively involved in eradicating infectious diseases by improving diagnostic testing; this initiative is expected to drive the adoption of diagnostic antibodies for testing.

Some of the notable initiatives for disease eradication are given below:

• The U.S. government, in the Fiscal Year 2021, funded $332 million for the TB control programs globally. The funding was used in more than 50 countries, including 20 of the 30 high burden countries. This funding is used for the prevention, detection, treatment, and R&D of TB.
• In 2021, the European Commission announced the ‘Europe’s Beating Cancer Plan.’ The plan included four key action areas. One of the key areas was early detection of cancer by improving access to better diagnostics and supporting the member states by ensuring that 90% of the EU population who are expected to have breast, cervical, and colorectal cancer are provided better services in diagnosis by 2025.
• In 2020, the CDC announced the strategic plan to eradicate hepatitis in the U.S. till 2030. The plan was aimed at developing and promoting hepatitis testing in the country.
• The U.S. Department of Health and Human Services (HHS), in 2019, announced the ‘Ending the HIV Epidemic in the U.S.’ plan. This initiative was aimed at eradicating HIV disease in the U.S. by 2030. This plan was launched to improve HIV prevention, diagnosis, and treatments.

Growing Prevalence of Diseases in Emerging Countries to Positively Impact Market

The high burden of diseases in emerging countries is expected to increase the demand for antibody-based test kits. According to the Cancer Tomorrow estimates, the number of cancer cases in China was estimated to be 4.57 million in 2020, and this number is projected to rise to 6.85 million in 2040. Similarly, the number of cancer cases in Brazil was estimated to rise to 995,000 by 2040 from 592,000 in 2020.

Furthermore, the International Diabetes Federation (IDF) estimated that in Mexico, 12.8 million cases of diabetes were reported in 2019, and this number is expected to increase to 22.3 million by 2045. Thus, the high prevalence of diseases is expected to increase the number of testing and positively impact market growth.

Key Findings in the Global Diagnostic Specialty Antibodies Market Study:

The Primary Antibody Segment Estimated to Generate Larger Proportion of Revenue in 2022

Primary antibodies are highly preferred over secondary antibodies due to their capability to directly bind with the targeted antigen. In addition, primary antibodies can recognize post-translational modifications (PTMs), such as glycosylation, phosphorylation, methylation, or acetylation. Furthermore, primary antibodies are mandatorily used in almost all assays. Hence, these factors attribute to the large market share of this segment.

Recombinant Antibody Segment Projected to Grow at Fastest CAGR During Forecast Period

Recombinant antibodies are more cost-effective than monoclonal antibodies and have a better affinity for binding to the target antigen. Also, recombinant monoclonal antibodies are produced in a shorter duration than other clonal antibodies. Hence, these factors drive its demand in the market.

ELISA Segment Expected to Account for the Largest Share in 2022

ELISA has a higher specificity, efficiency, and sensitivity and is relatively simple compared to western blot and other assays. These are the key factors promoting the demand for the ELISA technique. In addition, this test is also more cost-effective than IHC, western blot, and other assays, which further drives its demand in the market.

Unconjugated Antibodies Segment Expected to Grow at Fastest CAGR During Forecast Period

The specificity and sensitivity of unconjugated antibody is the prime factor driving its demand in the market. Furthermore, the demand for unconjugated antibodies for developing secondary antibody conjugates contributes to the growth of this segment.

Infectious Diseases Segment Expected to Account for Largest Share in 2022

The growth of the infectious diseases segment is attributed to the rising incidences of infectious diseases globally, resulting in the demand for diagnostic testing. The growing trend of self-testing kits and the increasing number of regulatory approvals of test kits for infectious diseases testing further contribute to the growth of this segment.

Asia-Pacific: Fastest growing regional market

The high market growth rate is attributed to the rising prevalence of diseases and the increasing incidences of unintended pregnancies in the region. In addition, factors such as funding availability for improving diagnosis and the rising number of government initiatives to eradicate infectious diseases, developments in the market, including product approvals and distribution agreements for antibody-based test kits, have further boosted the growth of this market in the region.

Key Players

The report includes a competitive landscape based on an extensive assessment of the key strategic developments adopted by leading market participants in the industry over the past three years. The key players profiled in the global diagnostic specialty antibodies market report are Abcam plc (U.K.), F. Hoffman La Roche Ltd. (Switzerland), Bio-Rad Laboratories, Inc. (U.S.), Creative Diagnostics (U.S.), Merck KGaA (Germany), Agilent Technologies, Inc. (U.S.), Becton, Dickinson and Company (U.S.), Rockland Immunochemicals, Inc. (U.S.), Santa Cruz Biotechnology (U.S.), Novus Biologicals, LLC (U.S.), and Thermo Fisher Scientific Inc. (U.S.).

Scope of the Report:

Diagnostic Specialty Antibodies Market, by Type

• Primary Antibodies
• Secondary Antibodies

Diagnostic Specialty Antibodies Market, by Clonality

• Monoclonal Antibodies
• Polyclonal Antibodies
• Recombinant Antibodies

Diagnostic Specialty Antibodies Market, by Technique

• ELISA
• Lateral Flow Assay
• Immunohistochemistry (IHC)
• Immunoprecipitation (IP)
• Western Blot (WB)
• Immunocytochemistry (ICC)
• Other Techniques
  (Other techniques include immunofluorescence, flow cytometry, in situ hybridization, dot blot, radioimmunoassay, and others)

Diagnostic Specialty Antibodies Market, by Conjugate

• Conjugated Antibodies
• Unconjugated Antibodies

Diagnostic Specialty Antibodies Market, by Application

• Infectious Diseases
  • Respiratory Infections
    • COVID-19
    • Influenza
    • Tuberculosis (TB)
    • Pneumonia
    • Other Respiratory Infections
      (Other respiratory infections include strep infections, pertussis, and respiratory syncytial virus (RSV), among others)
  • Parasitic Infections
    • Dengue
    • Malaria
    • Other Parasitic Infections
      (Other parasitic infections include leishmaniasis and zika, among others)
  • Gastrointestinal Infections (GI Infections)
    • Salmonellosis
    • Coli Infections
    • Other GI Infections
      (Other GI infections include cholera, Helicobacter pylori (H. pylori), and campylobacteriosis, among others)
  • Blood Borne Diseases
    • Hepatitis
    • HIV
    • Other Blood-Borne Infections
      (Other blood-borne infections include syphilis, chlamydia, and gonorrhea, among others)
  • Other Infectious Diseases
    (Other infectious diseases include sepsis, rubella, impetigo, and others)
• Oncology
• Pregnancy Detection/Fertility Testing
• Other Applications
  (Other applications include Alzheimer’s, autoimmune diseases and cardiac diseases, diabetes, and others)

Diagnostic Specialty Antibodies Market, by Geography

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • Rest of Europe (RoE)
• Asia-Pacific (APAC)
  • China
  • Japan
  • India
  • Rest of APAC (RoAPAC)
• Latin America
• Middle East & Africa

Key questions answered in the report: